XGen Pharmaceuticals DJB Revenue and Competitors

Big Flats, NY

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • XGen Pharmaceuticals DJB's estimated annual revenue is currently $13.9M per year.(i)
  • XGen Pharmaceuticals DJB's estimated revenue per employee is $201,000

Employee Data

  • XGen Pharmaceuticals DJB has 69 Employees.(i)
  • XGen Pharmaceuticals DJB grew their employee count by 3% last year.

XGen Pharmaceuticals DJB's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.3M617%N/AN/A
#2
$354.3M461-2%$567.1MN/A
#3
$377.1M1876-1%N/AN/A
#4
$7.8M398%N/AN/A
#5
$5.4M270%N/AN/A
#6
$45M2246%N/AN/A
#7
$6.8M34-82%N/AN/A
#8
$9.2M4612%N/AN/A
#9
N/A69446%N/AN/A
#10
$15.5M775%N/AN/A
Add Company

What Is XGen Pharmaceuticals DJB?

Approaching the end of a 20 year career at a major pharmaceutical company, Dan Badia made a discovery. Where larger companies found obsolescence in small markets or low-profit yielding drugs, Dan saw reliable solutions proven to be effective and affordable alternatives for healthcare. With his wife, Shirley Harmening, Dan founded a company in 1973 on a bridge table in his bedroom. In just 14 years, this company would outgrow its birthplace and find a home in lower upstate New York. That growth would be sustained by introducing injectables into an established product line, mainly consisting of anti-infective, compounding powders. In 2003, that company would become X-GEN Pharmaceuticals, Inc. Affirming Dan’s original vision while embracing a dynamic industry, family-owned X-GEN Pharmaceuticals, Inc. remained a leader in generic, anti-infective pharmaceuticals. In this our 50th year in affiliation, we honor this heritage by carrying our founder’s initials in our new name, XGen Pharmaceuticals DJB. With reverence for the past and a passion for the future, we expect big results, driven by bold solutions and delivered by real people.

keywords:N/A

N/A

Total Funding

69

Number of Employees

$13.9M

Revenue (est)

3%

Employee Growth %

N/A

Valuation

N/A

Accelerator